An interventional study of osteochondral transplant on the femoral condyle in Osteochondral Defect, sponsored by AlloSource. Recruiting at 6 sites in United States. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-11-25.
Sponsored by AlloSource · Not applicable, Interventional, and Treatment
The primary objective of this study is to obtain evidence of the effectiveness of Cryopreserved Osteochondral Allograft Core in the treatment of osteochondral lesions on the femoral condyle.
Patients between the ages of ≥12 years and ≤ 60 years who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 0.9-8.0 cm2 in size, and cystic changes requiring osseous repair, as confirmed by MRI , CT scan, or arthroscopy, and undergoing an osteochondral transplant procedure will be eligible for enrollment. Patients will receive one or more cryopreserved osteochondral allograft core transplants to replace damaged cartilage.
Patients will be followed for up to 60 months post-procedure (6 weeks, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months) to evaluate short and long-term outcomes of the procedure using the cryopreserved osteochondral allograft cores.
AlloSource is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Eligible and enrolled patients will receive one or more cryopreserved osteochondral allograft core as part of their osteochondral transplant procedure
Procedure: osteochondral transplant on the femoral condyle
Patients between the ages of ≥12 years and ≤ 60 years who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 0.9-8.0 cm2 in size, and cystic changes requiring osseous repair, as confirmed by MRI , CT scan, or arthroscopy and will undergo a osteochondral transplant by removing the damaged cartilage and replacing that cartilage with a cryopreserved osteochondral allograft core.
International Knee Documentation Committee (IKDC) score
Change of physical functioning and pain from baseline as assessed by the subjective International Knee Documentation Committee (IKDC) score. Scores are reported on a 0-100 scale, with low scores indicating worse outcomes and higher scores indicating better outcomes.
Time frame: 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months post procedure
Knee Injury and Osteoarthritis Outcome Score (KOOS)
Change from baseline (pre-operative) Scores are reported on a 0-100 scale, with low scores indicating worse outcomes and higher scores indicating better outcomes.
Time frame: 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Assessment of repair cartilage structure
Assessment of repair cartilage structure, using Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores, as measured by Magnetic Resonance Imaging (MRI). Scores are reported on a 0-100 scale, with low scores indicating worse outcomes and higher scores indicating better outcomes.
Time frame: 12 months, 24 months and 60 months post procedure
Graft incorporation
Assessment of graft incorporation using Magnetic Resonance Imaging (MRI)
Time frame: 12 months, 24 months and 60 months post procedure
12-item Veterans RAND (VR-12)
Change from baseline (pre-operative) The instrument is primarily used to measure health related quality of life, to estimate disease burden and to evaluate disease-specific benchmarks with other populations. The 12 items are summarized into two scores, a "Physical Health Summary Measure" and a "Mental Health Summary Measure."
Time frame: 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months post procedure
Revision surgery
Incidences of revision surgeries during study follow up time period
Time frame: 60 months post-procedure
Plan to share: No — After patients have signed the ICF and have been determined to meet the inclusion/exclusion criteria, the patient will be given a patient identification number that consists of a 2-digit site number and a 3-digit patient number. As allowed by governing privacy requirements, this will serve as a patient's identifier on all study-related documentation.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AlloSource